5 Star Reviews from Hundreds of Customers

Pioneering Pancreatic Cancer Care Through First-in-Class Discovery Engine

  • Treatments are customised to your unique goals
  • Achieve smoother, rejuvenated skin
  • Natural results that boost your confidence
BOOK Consultation

“It was a great experience and everything worked perfectly and the treatment happened successfully.”
Kiran S, London

meet the team

Leadership Team & PEN (Pancreatic Expert Network)

Executive Team

Darshan Gandhi, M.D., M.B.A., Harvard AMP

CEO and Co-Founder

Executive Team

David Setboun, Pharm.D, M.B.A., Harvard AMP

Executive Team

Eric Dutang, CPA, MBA

COO/CFO

Executive Team

Simon Mazza-Lunn, Ph.D

Scientific Advisor

Executive Team

Hemanta Baruah, Ph.D

Scientific Advisor

Pancreatic Expert Network

David Ting, MD

Pancreatic Expert Network

Professor Haiyong Han, Ph.D

Pancreatic Expert Network

Professor Rolf Brekken, Ph.D

Pancreatic Expert Network

Professor Daniel von Hoff, M.D

Pancreatic Cancer Unmet Need

Increasing Incidence

  • 2nd largest killer by 2030
  • >95% Mortality
  • Surpassed breast cancer

Lack of Rx

  • Only 5 FDA approved Rx
  • Response rates <20-30%
  • No maintenance Rx
  • Relapse <6 months
  • 5-year survival 11%

Regulatory (opportunity)

  • FDA open to smaller trials
  • Focus on patient stratification
  • Lower Threshold for approvals

Pancreatic Cancer Treatments have Significant Limitations

Targeted Therapy

Poor Penetration

  • Off-Target effects
  • Limited population
  • Small molecules
Sotorasib, Entrectinib, Rucaparib

Chemotherapy

Poor Penetration

  • Single agent response rates<20%
  • Combination too toxic
Gemcitabine, 5-FU, Oxaliplatin, Irinotecan

Immunotherapy

Limited population

  • MSI/TMB high
  • Suppressed TME
  • T-cell exhaustion
  • Poor penetration
Pembrolizumab Dostarlimab